







"The Trusted Marketplace for Pharmacies"

**Corporate Presentation
November 2020**



Safe Harbor Statement



The information set forth herein contains forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, including, but not limited to, statements regarding future operations, financial results, cash flows, costs and cost management initiatives, plans, expectations, projections, timelines, and operational and strategic initiatives, and can also be identified by the use of words like “will”, “may”, “can”, “could”, “should”, “predict”, “aim”, “potential”, “continue”, “opportunity”, “intend”, “goal”, “estimate”, “expect”, “expectations”, “project”, “projections”, “plans”, “anticipates”, “believe”, “think”, “confident”, “scheduled”, or similar expressions. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors. These risk factors and others are included from time to time in documents Trxade Group, Inc. files with the Securities and Exchange Commission (SEC), including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks and other filings with the SEC, available at the SEC’s website at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on Trxade Group, Inc.’s future results.

Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, Trxade Group, Inc.’s business, plans, prospects, financial condition, liquidity, cash flows, projections and results could differ materially from those expressed in any forward-looking statement. While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. Any forward-looking statement speaks only as of the date on which it is made. New risks and uncertainties arise over time, and it is not possible for us to predict the occurrence of those matters or the manner in which they may affect us. Except as required by law, Trxade Group, Inc. expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.

Past performance information given in this document is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

In this document, we may rely on and refer to information regarding our industry and the market for our products and services in general from market research reports, analyst reports and other publicly available information. Although we believe that this information is reliable, we cannot guarantee the accuracy and completeness of this information, and we have not independently verified any of it. Some data is also based on our good faith estimates.

The information set forth herein does not constitute an offer to sell or the solicitation of an offer to buy any securities of Trxade Group, Inc., nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

Use of Non-GAAP Financial Information

This presentation discusses “EBITDA” (earnings before interest, taxes, depreciation and amortization) and “Adjusted EBITDA” (EBITDA plus share in equity loss on investment and stock-based compensation). These measurements are not recognized in accordance with generally accepted accounting principles (GAAP) and should not be viewed as an alternative to GAAP measures of performance. EBITDA and Adjusted EBITDA are presented because we believe they provide additional useful information to investors due to the various noncash items during the period. EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider them in isolation, or as a substitute for analysis of our operating results as reported under GAAP. Some of these limitations are: EBITDA and Adjusted EBITDA do not reflect cash expenditures, future requirements for capital expenditures, or contractual commitments; EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, working capital needs; and EBITDA and Adjusted EBITDA do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on debt or cash income tax payments. Although depreciation and amortization are noncash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements. Additionally, other companies in our industry may calculate EBITDA and Adjusted EBITDA differently than Trxade Group, Inc. does, limiting its usefulness as a comparative measure. See appendix for reconciliation of these amounts to GAAP.

TRxADE Corporate Timeline



2010 - Founded by Suren Ajjarapu (CEO) and Prashant Patel (COO & president), investing a total of ~\$5.5M of their own capital

2013 - Launched second service to help pharmaceutical distributors' better source their pharmaceutical needs within a highly structured single platform

2013 - Software development completed, and first customer secured

2014 - Began trading as public company TRXD


2014 - Launched "RxGuru" to bring product information on a just-in-time basis to member base

2018 - Acquired Community Specialty Pharmacy, an accredited independent retail pharmacy with a focus on specialty medications

2017 - First quarter of profitability

2019 - Acquired Bonum Health Assets

2020 - Uplisted to NASDAQ: MEDS, sale of \$5 million of securities in underwritten offering of 0.8M shares at \$6.50



About TRxADE Group, Inc.



TRxADE is a technology & services company focused on a more effective process for purchasing and delivering prescription drugs to independent pharmacists & consumers

An Online Pharmaceutical Supply Chain Marketplace

- **Market Leader:** Operates the largest technology platform serving the pharmaceutical supply chain (similar to eBay or Kayak-style platform)
- **Disruptive Innovation:** Significantly lowering drug costs via a proprietary technology platform
- **Growing Rapidly:** Grew revenues 94% in 2019 & added +3,200 pharmacies to a total of 11,800
- **Profitable:** Positive operating profits in 10 of the last 12 quarters with strong margins
- **Robust Balance Sheet:** \$6.6 million in cash with limited debt
- **Experienced Management:** Management and Directors own ~54% of shares outstanding



Business to Business

Robust procurement technology platform that delivers lower cost, more transparent fulfillment process for independent pharmacists compared to industry norms



Business to Consumer

Turnkey service through a retail mail order specialty pharmacy, wholesale operations as drugs are increasingly ordered & delivered directly to consumers

TRxADE Group, Inc. (NASDAQ: MEDS)

Share Price ¹	\$6.20
Market Cap ¹	\$50.2M
Revenues (TTM) ³	\$17.1M
Gross Margin (TTM) ³	39.8%
Net Income (TTM) ³	\$(0.7)M
Q3 Adj. EBITDA ⁴	\$671K
Cash ²	\$6.6M
Debt ²	\$0.2M
Shares O/S ²	8.1M
Float ²	3.7M
Headquarters	Land O' Lakes, FL
Management Ownership ²	54%

1) As of October 26, 2020.

2) As of the quarter ended September 30, 2020.

3) TTM = Trailing twelve months ended September 30, 2020.

4) Adj. EBITDA is a non-GAAP term, net income before interest, taxes, depreciation and amortization as well as share in equity loss on investment and stock-based compensation. See appendix for reconciliation to GAAP.


Pharmaceutical Market Overview



U.S. Pharmaceutical Industry¹


- \$330 billion per year industry
- Over 65,000 pharmacy facilities & hundreds of state-licensed suppliers
- Excluding several large national chains, there are ~24,000 independent pharmacies in the U.S. that represent ~20% of all drug purchases (~\$93 Billion)
- Average annual sales per pharmacy are approximately \$3.5 million² & owners (typically 50+ years old) are looking for both more revenue channels & profits; as many prescriptions filled at independent pharmacists are done at a **LOSS** for the pharmacist

Independent Pharmacy Nationwide Footprint¹



Projected North America ePharmacy Market³ (USD Billion)

2014 – 2025 CAGR of 14.8%




1) Global Data
2) www.pbahealth.com
3) Grandview Research

Problem

- The existing market for prescription drugs is both large & growing; yet highly inefficient & costly
- Large pharmacy benefit managers (PBM), wholesalers & retail chains stifle competition to capture significant excess margin at the cost of the consumer, employers & government
- Suppliers, particularly the big 3 wholesalers (AmerisourceBergen Corporation, Cardinal Health & McKesson Corporation), often reprice/restock inventory daily

Solution

- TRxADE platform allows independent pharmacies to analyze “up-to-the-minute” supply & pricing on a cost-effective basis
- Increases transparency, while decreasing cost & time for independent pharmacies



Divisions of TRxADE Group, Inc.




Chart is purely illustrative and not representative of the Company's revenue mix

Divisions: TRxADE Marketplace



A Trusted Online Marketplace for the Pharmaceutical Supply Chain

The TRxADE Marketplace Platform utilizes a proprietary database & algorithms to identify pharmaceutical products that are likely to be in short supply & delivers them to independent pharmacies.

- Lower cost, more transparent fulfillment process for independent pharmacists compared to industry norms
- “Up-to-the-minute” supply & pricing on a cost-effective basis
- Historically reduces a pharmacy’s total annual purchase costs up to 7 - 10%



11,800+ Pharmacies*

Buying community benefits from
our buying power

Up to 50-90%
in cost savings

520+
Hours saved annually


Divisions: TRxADE Marketplace (cont'd)



11,800+ Pharmacies

- **Economies of scale** for purchase prices from large community of pharmacies purchases
- **No membership or transaction fees**
- **Eliminates negative reimbursement** – occurs when the beneficiary cost sharing (coinsurance/deductible), exceeds the reimbursement due to the provider

Safe, secure and easy to use web-based platform



Price transparency - Simple layout allows pharmacies to compare drugs offered by various suppliers & select the best deals

Access to multiple supplier sources



Divisions: Integra Pharma Solutions



Pharmaceutical Supplier of Quality Rx Products at Significant Savings

Integra Pharma Solutions is the pharmaceutical supplier of choice for healthcare organizations of all sizes. The Company's expertise in the distribution of products extends to all healthcare markets including Government Organizations, Hospitals, Clinics, and Independent Pharmacies nationwide.

- Currently in VAWD (Drug Distributor Accreditation) Pending Status
- Core Competencies in pharmaceuticals, diabetic supplies, veterinary and more
- \$800K+ in Awards from the US Department of Veterans Affairs
- 23K+ SKUs
- 500+ MFRs
- 60+ Supply Partners




Divisions: Bonum Health



Access to Board-Certified Providers & Health Assessment Tools, from Anywhere

Individually or through an employer sponsored program, patients can access board-certified medical providers nationwide using the Bonum Health mobile app, website or in the future, pending the outcome of pilot programs and a further roll-out, by visiting a Bonum Health Hub.

- Provides patients with 24/7/365 healthcare availability, with no insurance and long-term contracts necessary
- Telehealth services have expanded to supplemental offerings including Telemedicine, Hearing, Dental and Vision (coming soon)
- Offers Telehealth services to employers to provide health coverage to their employees without requiring health insurance
- Smart Technology and Bluetooth give Doctors and Specialty Providers the capability to view vitals via several integrations (FitBit, iHealth, Etc.)
- Dashboard to view past Doctor and Specialty Providers visits, keep track of appointments, care community and track vitals



NEW - Health technology bundle, Bonum Health+

Divisions: Direct to Consumer Sites



Sale of Products Direct to Consumers



Specialized care for patients suffering from chronic conditions with a focus on rare or difficult to find medications including oral medications, self-injectables and other supportive therapies.

- Medication therapy management (MTM) services
- Coordination of prior authorization (PA) with insurance companies
- Partnerships with telehealth vendors to improve patient access to care
- Consult providers with recommendations on drug therapy and improving outcomes




Key Operating Metrics



The main drivers of our growth strategy are simple...

Total Independent Pharmacies on TRxADE Platform




...Increase the number of independent pharmacies...

Average Number of Quarterly Purchases Per Pharmacy



...Increase the number of purchases per pharmacy...

Average Quarterly Purchase Size Per Pharmacy



...Increase the average amount spent per pharmacy...

Selected Financials




- **Rapid Growth:** 94% YoY growth in FY2019 with strong sequential growth
- **High Margin:** Revenue from transaction fees (Credit Card/PayPal model) does not include the drugs value (over \$100M annually), hence “tech like margins”
- **Built-Out Platform:** Continued platform development is always ongoing, but requires minimal capital investment on a go-forward basis
- **Positive Adj. EBITDA:** \$671K in adjusted EBITDA in Q3 2020*
- **Strong Balance Sheet:** \$6.6 million in cash with limited debt provides strong foundation for growth

(USD \$ in Millions)	TTM September 30, 2020	TTM September 30, 2019
Revenue	\$17.1	\$7.0
Gross Profit	\$6.8	\$4.5
Operating Income	\$(0.2)	\$0.2
Net Income (Loss)	\$(0.7)	\$0.0
(USD \$ in Millions)	September 30, 2020	September 30, 2019
Cash & Cash Equivalents	\$6.6	\$3.4
Debt	\$0.2	\$0.3

Annual Revenue Growth

(USD \$ in Thousands)



*Adj. EBITDA (Loss) is a non-GAAP term, net income before interest, taxes, depreciation and amortization as well as share in equity loss on investment and stock based compensation. See appendix for a reconciliation of these amounts to GAAP.



Suren Ajjarapu, Chairman of the Board, Chief Executive Officer and Secretary.

Mr. Ajjarapu has served as Chairman of the Board, Chief Executive Officer and Secretary since our acquisition of Trxade Group, Inc., a Nevada corporation (“Trxade Nevada”) (our predecessor company) on January 8, 2014, and as the Chairman of the Board, Chief Executive Officer and Secretary of Trxade Nevada since its inception. Mr. Ajjarapu has also served as Chairman of the Board for Feeder Creek Group, Inc., since March 2018. Feeder Creek Group, Inc. is a company involved in developing renewable natural gas sites in Iowa. Mr. Ajjarapu was a Founder, CEO and Chairman of Sansur Renewable Energy, Inc., a company involved in developing wind power sites in the Midwest, United States, from 2009 to 2012. Mr. Ajjarapu was a Founder, President and Director of Aemetis, Inc., a biofuels company (AMTX.OB) and a Founder, Chairman and Chief Executive Officer of International Biofuels, a subsidiary of Aemetis, Inc., from 2006 to 2009. Mr. Ajjarapu was Co-Founder, COO, and Director Global Information Technology, Inc., an IT outsourcing and systems design company, headquartered in Tampa, Florida with major operations in India from 1995 to 2006. Mr. Ajjarapu holds an MS in Environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in International Finance and Management. Mr. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.



Prashant Patel, Director, President and Chief Operating Officer

Mr. Patel has served as our full-time President and COO, and as a director, since our acquisition of Trxade Nevada on January 8, 2014, and as the COO and President and as a director of Trxade Nevada since its inception. Mr. Patel is a registered pharmacist and pharmaceutical consultant with over ten years of experience in retail pharmacy and pharmaceutical logistics and the founder of several pharmacies in the Tampa Bay, Florida area. Mr. Patel has been a President and Member of the Board of Trxade Nevada since August 2010. Since October 2008, Mr. Patel has been Managing Member of APAA LLC, a pharmacy. Since April 2007, Mr. Patel has been a Vice President of Holiday Pharmacy, Inc., a pharmacy. Mr. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, United Kingdom.



Howard A. Doss, Chief Financial Officer

Mr. Doss has served as the CFO of Trxade Group, Inc. since January 2014. Mr. Doss has served in a variety of capacities with accounting and investment firms. He joined the staff of Seidman & Seidman (BDO Seidman, Dallas) in 1977 and, in 1980, he joined the investment firm Van Kampen Investments, opening the firm’s southeast office in Tampa, Florida in 1982. He remained with the firm until 1996 when he joined Franklin Templeton to develop corporate retirement plan distribution. After working for the Principal Financial Group office in Tampa, Florida, Mr. Doss was City Executive for U.S. Trust in Sarasota, Florida, responsible for high net worth individuals. He retired from that position in 2009. He served as CFO and Director for Sansur Renewable Energy an alternative energy development company, from 2010 to 2012. Mr. Doss has also served as President of STARadio Corp. since 2005. Mr. Doss is a member of the America Institute of CPA’s. He is a graduate of Illinois Wesleyan University

Key Takeaways (NASDAQ: MEDS)




TRxADE is a technology and services company focused on a more effective process for purchasing and delivering prescription drugs to independent pharmacists and consumers.

A Tech-Enabled Pharmaceutical Supply Chain Marketplace


- **Market Leader:** Operates the largest technology platform serving the pharmaceutical supply chain (similar to an eBay or Kayak-style platform)
- **Innovator:** Significantly lowering drug costs via a proprietary technology platform
- **Built-Out Platform:** Platform development requires minimal capital investment on a go-forward basis
- **Expansion:** Further expansion to address new market opportunities to leverage TRxADE's industry expertise & network of 11,800+ independent pharmacy partners
- **Profitable:** Positive operating profits in 10 of the last 12 quarters with tech-like margins
- **Rapidly Growing:** Grew revenues 94% in 2019 with over 3,200 new pharmacy users
- **Robust Balance Sheet:** \$6.6 million in cash with limited debt
- **Experienced Management:** Management and Directors own ~54% of shares outstanding

Annual Revenue Growth

(USD \$ in Thousands)



Contact



Investor Relations Contact

Greg Falesnik

Luke Zimmerman

MZ North America

Main: 949-259-4987

MEDS@mzgroup.us

www.mzgroup.us

TRxADE Group, Inc.

3840 Land O' Lakes Boulevard

Land O'Lakes, FL 34639

(800) 261-0281

www.trxadegroup.com

www.trxade.com

www.rxintegra.com

www.bonumhealth.com

www.comsprx.com

Appendix: Consolidated Balance Sheets



	September 30, 2020	December 31, 2019
Assets		
Current Assets		
Cash	\$ 6,647,763	\$ 2,871,694
Accounts Receivable, net	1,034,482	792,050
Inventory	1,647,088	56,761
Prepaid Assets	232,671	82,452
Deposits for Inventory purchases	1,081,250	-
Total Current Assets	10,643,254	3,802,957
Property Plant and Equipment, Net	150,147	174,987
Other Assets		
Deposits	21,636	21,636
Deferred Offering Costs	-	88,231
Right-of-use leased assets	313,000	757,710
Goodwill	725,973	725,973
Total Assets	<u>\$ 11,854,010</u>	<u>\$ 5,571,494</u>
Liabilities and Shareholders' Equity		
Current Liabilities		
Accounts Payable	\$ 191,597	\$ 334,614
Accrued Liabilities	286,145	98,852
Current Portion Lease Liabilities	57,155	87,350
Total Current Liabilities	534,897	520,816
Long Term Liabilities		
Notes Payable – Related Parties	225,000	225,000
Other Long-term Liabilities – Leases	267,024	685,461
Total Liabilities	1,026,921	1,431,277
Shareholders' Equity		
Series A Preferred Stock, \$0.00001 par value; 10,000,000 shares authorized; none issued and outstanding as of September 30, 2020 and December 31, 2019, respectfully	-	-
Common Stock, \$0.00001 par value; 100,000,000 shares authorized; 8,070,671 and 6,539,415 shares issued and outstanding, as of September 30, 2020 and December 31, 2019, respectively	81	65
Additional Paid-in Capital	19,446,404	12,535,655
Retained Deficit	(8,619,396)	(8,395,503)
Total Shareholders' Equity	10,827,089	4,140,217
Total Liabilities and Shareholders' Equity	<u>\$ 11,854,010</u>	<u>\$ 5,571,494</u>

Appendix:

Consolidated Statements of Operations



Trxade Group, Inc.
Consolidated Statements of Operations
For the Three and Nine Months Ended September 30, 2020 and 2019
(unaudited)

	Three months ended		Nine months ended	
	2020	2019	2020	2019
Revenues	\$ 6,332,269	\$ 2,311,426	\$ 15,128,226	\$ 5,740,361
Cost of Sales	4,402,967	1,000,917	9,554,016	2,119,894
Gross Profit	1,929,302	1,310,509	5,574,210	3,620,467
Operating Expenses				
General and Administrative	1,783,481	1,132,656	5,775,439	3,138,150
Operating Income (Loss)	145,821	177,853	(201,229)	482,317
Other Income	-	25,275	-	25,275
Investment Loss	-	(162,178)	-	(250,000)
Interest Expense	(7,430)	(13,385)	(22,664)	(46,817)
Net Income (Loss)	\$ 138,391	\$ 27,565	\$ (223,893)	\$ 210,775
Net Income (Loss) per Common Share – Basic:	\$ 0.02	\$ 0.00	\$ (0.03)	\$ 0.04
Net Income (Loss) per Common Share – Diluted:	\$ 0.02	\$ 0.00	\$ (0.03)	\$ 0.03
Weighted average Common Shares Outstanding – Basic	8,063,043	5,748,329	7,572,954	5,728,421
Weighted average Common Shares Outstanding - Diluted	8,215,418	6,047,748	7,725,329	6,027,840

Appendix:

Reconciliation of Net Income to Adj. EBITDA



	For the three months ended September 30,		For the nine months ended September 30,	
	2020	2019	2020	2019
Net Income (loss) attributable to Trxade Group, Inc.	\$ 138,391	\$ 27,565	\$ (223,893)	\$ 210,775
Add (deduct):				
Interest, net	7,430	13,385	22,664	46,817
Depreciation and amortization	1,250	1,250	3,750	3,750
EBITDA	147,071	42,200	(197,479)	261,342
Add (deduct):				
Share in Equity losses on Investment	-	162,178	-	250,000
Stock-based compensation	524,018	64,011	1,700,170	167,957
Adjusted EBITDA *	\$ 671,089	\$ 268,389	\$ 1,502,691	\$ 679,299

*EBITDA and Adjusted EBITDA are non-GAAP financial measures. These measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance. See also “Use of Non-GAAP Financial Information”, above.